Literature DB >> 24490606

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.

Haïdar Saadoun1, Pierre-Jean Lamy, Simon Thezenas, Stéphane Pouderoux, Frédéric Bibeau, Frédéric Montels, Gilles Romieu, Pierre-Emmanuel Colombo, Marian Gutowski, William Jacot.   

Abstract

AIMS: Following the introduction of new adjuvant therapies we wanted to reappraise the prognostic and predictive value of uPA/PAI-1 in early breast cancer. PATIENTS &
METHODS: This monocentric retrospective study included 652 patients who had curative surgery between 2006 and 2011 and adjuvant treatment decision-making, taking into account uPA/PAI-1 tumor levels.
RESULTS: uPA and PAI-1 levels were associated with classical clinicopathological parameters and adjuvant chemotherapy decision, but not with peritumoral vascular invasion (PVI; also known as peritumoral vascular emboli). HER2 overexpression, PVI and uPA/PAI-1 levels were not significantly associated with relapse-free survival in univariate analysis. In multivariate analysis, T stage, N stage and progesterone receptors were the only independent relapse-free survival predictive factors.
CONCLUSION: The absence of an association between uPA/PAI-1 and PVI allows their concomitant consideration in adjuvant treatment discussion. The overall good prognosis of patients with high uPA/PAI-1 levels might be linked to the uPA/PAI-1 predictive value and the inclusion of these parameters in adjuvant guidelines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24490606     DOI: 10.2217/fon.13.177

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  7 in total

1.  Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry.

Authors:  C F Singer; S W Jahn; M Rudas; Z Bago-Horvath; F Fitzal; L Abete; F Moinfar; M Gnant; M Filipits
Journal:  Breast       Date:  2022-05-19       Impact factor: 4.254

Review 2.  TRPM8: a potential target for cancer treatment.

Authors:  Zhaoguo Liu; Hongyan Wu; Zhonghong Wei; Xu Wang; Peiliang Shen; Siliang Wang; Aiyun Wang; Wenxing Chen; Yin Lu
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-23       Impact factor: 4.553

3.  A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.

Authors:  Lindsay B Alcaraz; Aude Mallavialle; Timothée David; Danielle Derocq; Frédéric Delolme; Cindy Dieryckx; Caroline Mollevi; Florence Boissière-Michot; Joëlle Simony-Lafontaine; Stanislas Du Manoir; Pitter F Huesgen; Christopher M Overall; Sophie Tartare-Deckert; William Jacot; Thierry Chardès; Séverine Guiu; Pascal Roger; Thomas Reinheckel; Catherine Moali; Emmanuelle Liaudet-Coopman
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

4.  High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.

Authors:  Eun Young Kim; Sung-Im Do; Keehoon Hyun; Yong Lai Park; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn; Chan Heun Park
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

5.  Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.

Authors:  Elise Deluche; Laurence Venat-Bouvet; Sophie Leobon; Veronique Fermeaux; Joelle Mollard; Nadira Saidi; Isabelle Jammet; Yves Aubard; Nicole Tubiana-Mathieu
Journal:  BMC Cancer       Date:  2017-09-27       Impact factor: 4.430

6.  Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.

Authors:  Yahya Ashraf; Hanane Mansouri; Valérie Laurent-Matha; Lindsay B Alcaraz; Pascal Roger; Séverine Guiu; Danielle Derocq; Gautier Robin; Henri-Alexandre Michaud; Helène Delpech; Marta Jarlier; Martine Pugnière; Bruno Robert; Anthony Puel; Lucie Martin; Flavie Landomiel; Thomas Bourquard; Oussama Achour; Ingrid Fruitier-Arnaudin; Alexandre Pichard; Emmanuel Deshayes; Andrei Turtoi; Anne Poupon; Joëlle Simony-Lafontaine; Florence Boissière-Michot; Nelly Pirot; Florence Bernex; William Jacot; Stanislas du Manoir; Charles Theillet; Jean-Pierre Pouget; Isabelle Navarro-Teulon; Nathalie Bonnefoy; André Pèlegrin; Thierry Chardès; Pierre Martineau; Emmanuelle Liaudet-Coopman
Journal:  J Immunother Cancer       Date:  2019-02-04       Impact factor: 13.751

7.  Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.

Authors:  Mathilde Guerin; Anthony Gonçalves; Yves Toiron; Emilie Baudelet; Matthieu Pophillat; Samuel Granjeaud; Patrick Fourquet; William Jacot; Carole Tarpin; Renaud Sabatier; Emilie Agavnian; Pascal Finetti; José Adelaide; Daniel Birnbaum; Christophe Ginestier; Emmanuelle Charafe-Jauffret; Patrice Viens; François Bertucci; Jean-Paul Borg; Luc Camoin
Journal:  Oncotarget       Date:  2018-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.